Compare Stocks

→ Trump just won 2024 (From Porter & Company) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NVAX Novavax	$4.67 +7.9%	$4.71	$3.53 ▼ $11.36	$653.57M	1.59	7.29 million shs	5.44 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NVAX Novavax	+0.93%	+3.34%	-9.41%	+8.25%	-43.91%

Trump’s last act as President (Ad)

You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines.

For the full story, click here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NVAX Novavax	3.7442 of 5 stars	3.5	2.0	0.0	4.7	1.7	0.8	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NVAX Novavax	3.00	Buy	$17.00	264.03% Upside

Current Analyst Ratings

Latest NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/1/2024	NVAX Novavax	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$35.00 ➝ $19.00

(Data available from 5/1/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NVAX Novavax	$983.71M	0.66	N/A	N/A	($6.04) per share	-0.77

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NVAX Novavax	-$545.06M	-$5.53	N/A	N/A	N/A	-55.41%	N/A	-32.63%	5/14/2024 (Estimated)

Latest NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/28/2024	Q4 2023	NVAX Novavax	-$0.49	-$1.44	-$0.95	-$1.44	$310.96 million	$291.34 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NVAX Novavax	N/A	0.70	0.67

Ownership

Institutional Ownership

Company	Institutional Ownership
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
NVAX Novavax	0.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
NVAX Novavax	1,543	139.95 million	138.69 million	Optionable

NVAX Headlines

Source	Headline
	Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know zacks.com - April 30 at 7:15 PM
	Novavax (NASDAQ:NVAX) Trading 4.4% Higher marketbeat.com - April 30 at 5:35 PM
	Novavax, Inc. (NASDAQ:NVAX) is Shah Capital Management's 4th Largest Position marketbeat.com - April 29 at 7:07 PM
	3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole fool.com - April 29 at 8:10 AM
	Novavax (NVAX) Dips More Than Broader Markets: What You Should Know msn.com - April 26 at 1:15 AM
	Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement accesswire.com - April 25 at 12:30 PM
	3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition investorplace.com - April 25 at 6:00 AM
	Validea Detailed Fundamental Analysis - NVAX nasdaq.com - April 24 at 5:18 PM
	Novavax COVID jab delivered by indie pharmacy in UK first chemistanddruggist.co.uk - April 23 at 9:32 PM
	Novavax (NASDAQ:NVAX) Trading Up 6.4% marketbeat.com - April 23 at 1:27 PM
	These Biotech Stocks Could Soar 120% and 295%, According to Wall Street fool.com - April 21 at 5:08 AM
	Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement accesswire.com - April 18 at 12:15 PM
	Novavax gets grant for coronavirus spike proteins for stable and immunogenic vaccines pharmaceutical-technology.com - April 17 at 12:11 PM
	Novavax Availability Dooms Christian Workers’ Covid Vaccine Suit news.bloomberglaw.com - April 16 at 3:58 PM
	Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement accesswire.com - April 16 at 12:30 PM
	Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says msn.com - April 15 at 6:28 PM
	Activist hedge fund seeks big shake-up at Novavax pharmaphorum.com - April 15 at 1:28 PM
	Novavax comes under pressure from activist investor as COVID sales fall short fiercepharma.com - April 15 at 1:28 PM
	Raleigh hedge fund urges board shakeup at Novavax bizjournals.com - April 15 at 1:28 PM
	Novavax (NASDAQ:NVAX) Jumps Amid Activist Investor Push msn.com - April 15 at 1:28 PM
	US-based Hedge fund Shah Capital urges Novavax board shake-up: Report business-standard.com - April 15 at 8:27 AM
	Shah Capital calls for board shake-up at Novavax msn.com - April 15 at 8:27 AM
	Shah Capital nominates two highly qualified independent director candidates for Novavax finance.yahoo.com - April 15 at 8:27 AM
	Hedge fund Shah Capital recommends two new candidates for Novavax board reuters.com - April 15 at 6:43 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Novavax

NASDAQ:NVAX

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial